Jutta Prade



close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Epilepsy-related functional brain network alterations are already present at an early age in the GAERS rat model of genetic absence epilepsy (2024) Wachsmuth L, Hebbelmann L, Prade J, Kohnert LC, Lambers H, Lüttjohann A, Budde T, et al. Journal article Prediction of response to Certolizumab-Pegol in rheumatoid arthritis (PreCePRA) by functional MRI of the brain – Study protocol for a randomized double-blind controlled study (2021) Schenker H, Tascilar K, Konerth L, Sergeeva M, Prade J, Strobelt S, Kleyer A, et al. Journal article Brain fMRI Predicts Responses to Certolizumab Pegol in RA. an International, Multi-center, Randomized, Double-blind, Placebocontrolled Trial (PreCePRA) (2020) Rech J, Schenker H, Tascilar K, Hagen M, Kleyer A, Simon D, Mendez LV, et al. Conference contribution CENTRAL NERVOUS SYSTEM PAIN RESPONSE AND COMPONENTS OF DISEASE ACTIVITY IN RA PATIENTS AFTER TREATMENT WITH CERTOLIZUMAB OR PLACEBO: A POST-HOC ANALYSIS FROM THE PRECEPRA TRIAL (2020) Schenker H, Rech J, Tascilar K, Hagen M, Schoenau V, Sergeeva M, Selvakumar M, et al. Conference contribution PREDICTION OF RESPONSE TO CERTOLIZUMAB PEGOL TREATMENT BY FUNCTIONAL MRI OF THE BRAIN: AN INTERNATIONAL, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (PRECEPRA) (2020) Rech J, Tascilar K, Schenker H, Sergeeva M, Selvakumar M, Konerth L, Prade J, et al. Conference contribution LONGITUDINAL CHANGE IN THE CENTRAL NERVOUS SYSTEM PAIN RESPONSE AFTER TREATMENT WITH CERTOLIZUMAB OR PLACEBO. A POST-HOC ANALYSIS FROM THE PRECEPRA TRIAL (2020) Rech J, Tascilar K, Schenker H, Hagen M, Sergeeva M, Selvakumar M, Konerth L, et al. Conference contribution Prediction of Response to Certolizumab-Pegol in Rheumatoid Arthritis By Functional MRI of the Brain - an Interim Analysis of an Ongoing Investigator Initiated Phase III Trial (2017) Schenker H, Heß A, Konerth L, Sergeeva M, Prade J, Kleyer A, Reiser M, et al. Conference contribution